Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Equity (2016 - 2025)

Historic Return on Equity for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to 0.1%.

  • Theravance Biopharma's Return on Equity rose 3600.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year increase of 3600.0%. This contributed to the annual value of 0.33% for FY2024, which is 1600.0% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Return on Equity is 0.1%, which was up 3600.0% from 0.03% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Return on Equity registered a high of 15.09% during Q3 2022, and its lowest value of 0.39% during Q1 2025.
  • Moreover, its 5-year median value for Return on Equity was 0.16% (2023), whereas its average is 1.1%.
  • Per our database at Business Quant, Theravance Biopharma's Return on Equity surged by 149800bps in 2022 and then tumbled by -152600bps in 2023.
  • Theravance Biopharma's Return on Equity (Quarter) stood at 0.2% in 2021, then soared by 1155bps to 2.09% in 2022, then plummeted by -111bps to 0.24% in 2023, then plummeted by -47bps to 0.35% in 2024, then skyrocketed by 127bps to 0.1% in 2025.
  • Its Return on Equity stands at 0.1% for Q3 2025, versus 0.03% for Q2 2025 and 0.39% for Q1 2025.